Cui Weitong, Chen Xingyu, Zhu Junyao, Zhang Mei, Xiao Dexuan, Qin Xin, Zhang Tianyi, Lin Yunfeng
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Nanoscale. 2020 Aug 28;12(33):17196-17202. doi: 10.1039/d0nr03731a.
Zoledronic acid (ZA) is a bisphosphonate (BP) drug that has been widely used in clinical treatments as a potent bone resorption inhibitor. In recent years, an increasing number of cases of bisphosphonate-associated osteonecrosis of the jaw (BRONJ) have been reported. This is a severe maxillofacial complication characterized clinically by bone exposure, necrosis, pain, and halitosis. Its pathogenesis is still not clear, and there is no effective clinical treatment known. Therefore, prevention of BRONJ is especially important. To provide a new research direction for the treatment of BRONJ, this study used a new tetrahedral framework nucleic acid (TFNA), which can antagonize the inhibitory effect of ZA on the differentiation and maturation of osteoclasts (OCs). In vivo and in vitro experiments showed that TFNAs at a specific concentration exhibited no cytotoxicity and could reverse the inhibition of ZA on OC differentiation and maturation, effectively inhibiting the formation of BRONJ.
唑来膦酸（ZA）是一种双膦酸盐（BP）药物，作为一种强效的骨吸收抑制剂已被广泛应用于临床治疗。近年来，双膦酸盐相关颌骨坏死（BRONJ）的病例报告越来越多。这是一种严重的颌面并发症，临床特征为骨暴露、坏死、疼痛和口臭。其发病机制仍不清楚，目前尚无有效的临床治疗方法。因此，预防BRONJ尤为重要。为了为BRONJ的治疗提供新的研究方向，本研究使用了一种新型四面体框架核酸（TFNA），它可以拮抗ZA对破骨细胞（OC）分化和成熟的抑制作用。体内和体外实验表明，特定浓度的TFNA无细胞毒性，可逆转ZA对OC分化和成熟的抑制作用，有效抑制BRONJ的形成。
